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N-type calcium channel; renal fibrosis; unilateral ureteral obstruction; epithelial-mesenchymal transition THE RENAL SYMPATHETIC NERVES innervate the tubules, the vessels, and the juxtaglomerular granular cells of the kidney (5) . Renal sympathetic nerve activation reduces urinary sodium and water excretion by increasing renal tubular water and sodium reabsorption throughout the nephron. It also decreases renal blood flow and glomerular filtration rate by constricting the renal vasculature and activates the renin-angiotensin system (RAS) by stimulating renin release from juxtaglomerular granular cells. Conversely, angiotensin II stimulates sympathetic nerve activity through central mechanisms and by facilitating adrenergic neurotransmission at the sympathetic nerve terminal, thus suggesting significant interactions between renal sympathetic nerves and the RAS in the control of renal function (4) . N-type Ca 2ϩ channels are densely distributed in the sympathetic nervous system and play a predominant role in neurotransmitter release from the nerve endings of sympathetic neurons (8) . In patients with chronic renal diseases, increased sympathetic nerve activity and plasma renin activity are observed (10), thus suggesting that sympathetic nerve activity via N-type Ca 2ϩ channels is involved in renal injury. Renal fibrosis is the common end point of virtually all progressive kidney diseases (1). Emerging evidence indicates that a large proportion of interstitial fibroblasts, primarily responsible for extracellular matrix accumulation, originate from tubular epithelial cells via epithelial-to-mesenchymal transition (EMT) in the fibrotic kidney. In the process of EMT, tubular epithelial cells acquire a fibroblastic phenotype and migrate into the interstitium through the destroyed tubular basement membrane (9) . We recently identified a population of tubular cells that participate in EMT during renal fibrosis (32) . Using in vivo labeling by bromodeoxyuridine (BrdU), we detected slow-cycling cells that infrequently pass through the cell cycle to maintain a pool of cells for tissue turnover and repair. After BrdU labeling followed by a chase period, slowcycling cells were identified as label-retaining cells (LRCs). LRCs were present in tubules of normal rat kidneys (20) . After ischemic injury, LRCs divided into numerous daughter cells, which actively proliferated and differentiated into tubular epithelial cells. These data suggest that LRCs act as a source of regenerating cells during the recovery process of the kidney after injury. In vitro analysis demonstrated that LRCs show phenotypic plasticity, tubulogenic capacity, and integration capacity into the developing kidney (19) . In a rat unilateral ureteral obstruction (UUO) model, LRCs were localized to both tubules and the interstitium of the fibrotic kidney. LRCs proliferated and migrated into the interstitium through the destroyed tubular basement membrane (32) , thus suggesting that LRCs undergo EMT during renal fibrosis (17) .
In the present study, we compared the effects of amlodipine (an L-type Ca 2ϩ channel blocker) and cilnidipine (a dual L/N-type Ca 2ϩ channel blocker) on fibrotic changes using a rat UUO model. We found that cilnidipine has an antifibrotic effect that was more potent than that of amlodipine. As with a previous study (32) , we detected LRCs in renal tubules of normal kidneys using in vivo BrdU labeling. Some LRCs were localized in the interstitium, expressed ␣-smooth muscle actin (␣-SMA) and vimentin, and produced several extracellular matrixes in UUO kidneys. Treatment with cilnidipine, but not amlodipine, significantly decreased the number of interstitial LRCs, suggesting the possibility that EMT in UUO kidneys was reduced by cilnidipine. These data imply that N-type Ca 2ϩ channels are involved in multiple steps of renal fibrosis. Blockade of N-type Ca 2ϩ channels may be a useful therapeutic approach for prevention of renal fibrosis.
MATERIALS AND METHODS

UUO.
Male Wistar rats (200 g) were purchased from Oriental Bio Service (Kyoto, Japan). UUO was performed as described previously (31) . Briefly, after induction of general anesthesia by intraperitoneal injection of pentobarbital (50 mg/kg body wt), the abdominal cavity was exposed via a midline incision and the left ureter was ligated at two points with 2-0 silk. At the indicated times after UUO, rats were killed and the kidneys were removed for histological examination. Ureteral obstruction was confirmed by observing dilation of the pelvis and proximal ureter, and collapse of the distal ureter. Sham-operated rats had their ureters exposed and manipulated but not ligated. In a separate experiment, cilnidipine (kindly provided by Ajinomoto, Kawasaki, Japan) or amlodipine (Sigma, St. Louis, MO) was administered orally in rat chow for 14 days at an approximate dose of 3 mg·kg Ϫ1 ·day Ϫ1 based on food intake. Arterial blood pressure was measured at the indicated time points using a programmable apparatus by the tail-cuff method. Serum creatinine and blood urea nitrogen levels were assessed by a Hitachi 7180 autoanalyzer (Hitachi HighTechnologies, Tokyo, Japan).
The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of Gunma University.
Immunohistochemical analysis. Immunostaining was performed using VECTASTAIN ABC-kit (Vector Laboratories) as described previously (21) . Briefly, paraffin sections (4 m) were deparaffinized, hydrated according to standard methods, soaked in blocking serum, and incubated with primary antibody overnight at 4°C. After being washed with PBS, sections were incubated with peroxidase-conjugated secondary antibody, followed by reaction with diaminobenzidine, and were counterstained with periodic acid-Schiff.
Indirect fluorescent immunostaining was performed as follows (18 incubated with fluorescence-labeled secondary antibodies and DAPI. Fluorescent images were recorded as described previously (18) . Primary antibodies were as follows: rabbit anti-rat Cav1.2 (␣1C subunit of L-type Ca 2ϩ channel) antibody and rabbit anti-rat Cav2.2 (␣1B subunit of N-type Ca 2ϩ channel) antibody (Alomone Labs, Jerusalem, Israel); mouse anti-aquaporin (AQP) 1 antibody (Abcam, Cambridge, UK); goat anti-Tamm-Horsfall glycoprotein (THP) antibody; goat anti-AQP 2 antibody, goat anti-proliferating cell nuclear antigen (anti-PCNA) antibody, and mouse anti-␤-actin antibody (BioVision Research Products); mouse monoclonal anti-␣-SMA antibody (Sigma); rabbit anti-laminin antibody and rabbit anti-type IV collagen antibody (Progen Biotecnik, Heidelberg, Germany); rabbit anti-rat type I collagen antibody, rabbit anti-mouse type III collagen antibody, and rabbit anti-bovine fibronectin antibody (LSL, Tokyo, Japan); rabbit anti-human vimentin antibody (Cell Signaling Technology, Denver, MA); mouse anti-rat CD68 antibody (Serotec, Oxford, UK); and goat anti-E-cadherin antibody (BD Transduction Laboratories, Franklin Lakes, NJ).
Morphological examination. Sections (4 m) were cut from paraffin blocks and were stained with hematoxylin-eosin or Masson's trichrome. With the use of Masson's trichrome -stained sections, the collagenous, fibrotic areas were quantified in 10 random cortical fields at ϫ200 magnification using Image J software. All glomeruli and vessels were subtracted from a given field, yielding a target area of tubulointerstitium.
Western blot analyses. Tissues were lysed in M-PER Mammalian Protein Extraction Reagent (Pierce, Rockford, IL). After centrifugation, the supernatant was collected, and the protein concentration was determined with the BCA protein assay kit (Pierce). Twenty micrograms of protein from each sample were separated by SDS-PAGE and transferred to a polyvinylidene difluoride membrane (Millipore, Bedford, MA). To reduce nonspecific antibody binding, the membrane was blocked with 5% nonfat milk, incubated with primary antibody for overnight at 4°C, and washed with Tris-buffered saline (20 mM Tris·HCl, 150 mM NaCl, and 0.05% Tween 20) . After incubation with alkaline phosphatase-conjugated secondary antibodies for 2 h, the membrane was washed with Tris-buffered saline. Membranes were washed again and reacted with substrate (Sigma FAST BCIP/NBT; Sigma). Primary antibodies were as follows: rabbit anti-rat Cav1.2 (␣1C subunit of L-type Ca 2ϩ channel) antibody and rabbit anti-rat Cav2.2 (␣1B subunit of N-type Ca 2ϩ channel) antibody (Alomone Labs); mouse anti-␤-actin antibody (BioVision Research Products); and mouse monoclonal anti-␣-SMA antibody (Sigma).
In vivo BrdU labeling. LRCs were detected by BrdU labeling as described previously (20) with slight modification. Briefly, ALZET osmotic pumps (Durect, Cupertino, CA) containing BrdU (140 mg) were placed in the peritoneal cavity of rats. After 1 wk, osmotic pumps were removed, and 2 wk later, rats were killed and kidneys were removed for histological analysis. At this dose, animals appeared healthy with normal kidney histology during the whole experimental Values are means Ϯ SE (n ϭ 6). *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001. Contra, contralateral; Cil, cilnidipine; Aml, amlodipine; BUN, blood urea nitrogen. B: renal function of rats at 14 days after UUO. Values are means Ϯ SE (n ϭ 5). ***P Ͻ 0.001 vs. sham.
# P Ͻ 0.05 vs. UUO. C: fibrotic area in UUO kidneys of untreated, cilnidipine-treated, and amlodipine-treated rats was assessed by Masson's trichrome staining. Magnification: ϫ100. D: quantitative analysis of fibrotic area. Values are means Ϯ SE (n ϭ 5). *P Ͻ 0.05, **P Ͻ 0.01. E: expression of type I and type III collagen in the kidneys at 7 days after UUO was examined by immunostaining. Magnification: ϫ200. F and G: quantitative analysis of type I (F) and type III (G) collagen-positive area. Values are means Ϯ SE (n ϭ 5). *P Ͻ 0.05, ***P Ͻ 0.001 vs. none.
course. BrdU-positive cells were detected using a cell proliferation kit (Amersham, Piscataway, NJ) according to the manufacturer's instructions and were counterstained with periodic acid-Schiff. Quantitative analysis of LRCs was performed by counting BrdU-positive nuclei in the tubular area or in the interstitial area from five randomly selected fields under a light microscope at ϫ200 magnification. The average of five determinants was calculated. The number of tubular or interstitial LRCs was quantified and expressed as a percentage of total tubular or interstitial cells per field, respectively. The number of PCNA-positive cells was also quantitatively analyzed in a similar manner.
Real-time PCR. Tissues were homogenized by using microhomogenator, and total RNAs were extracted using RNAiso (Takara, Tokyo, Japan). First-strand cDNA was made from total RNA using Super Script III First-Strand (Invitrogen, Carlsbad, CA) according to the manufacturer's instruction. Real-time PCR was performed by the ABI 7300 Real-time PCR System (Applied Biosystems, Foster City, CA). Reactions included 5 l of a SYBR Green RealtimePCR MasterMix (TOYOBO, Osaka, Japan), 0.2 l 3=-primer, 0.2 l 5=-primer, and 1 l cDNA. Samples were incubated at 50°C for 2 min and then at 95°C for 5 min, followed by 40 cycles of 15 s at 95°C, and 60 s at 58°C (Cav1.2) or at 55°C (Cav2.2). The expression of Cav1.2 or Cav2.2 and GAPDH in each sample was quantified in separate tubes with the following primers: rat Cav1.2 (sense and antisense: 5=-CAGCAGGTCCTATGTCAGCA-3= and 5=-CCGACAGCAGT-GAATGAAGA-3=, respectively), rat Cav2.2 (sense and antisense: 5=-TGCCAACATCTCCATTGCT-3= and 5=-AGTTCTGCTGCGGT-GAGTTT-3=, respectively), and rat GAPDH (sense and antisense: 5=-TGCCAACATCTCCATTGCT-3= and 5=-AGTTCTGCTGCGGT-GAGTTT-3=). All data were expressed as the relative differences between normal and contralateral or UUO kidneys after normalization to GAPDH expression. Gels of the PCR products after quantification of the indicated genes by real-time PCR showed single bands (Cav1.2, 158 basepair; Cav2.2, 91 basepair; and GAPDH, 307 basepair, respectively) in which the band size was the same as expected (data not shown).
Statistical analysis. Differences between means were compared by Student's t-test, with P values of Ͻ0.05 considered to be significant. (Fig. 1A) . We also examined the expressions of the L-type Ca 2ϩ channel and N-type Ca 2ϩ channel in normal, contralateral, and UUO kidneys by Western blotting. Unlike the data from previous report showing that L-type Ca 2ϩ channel was detectable in normal kidneys (33) , the expressions of both L-type and N-type Ca 2ϩ channels were undetectable in normal (data not shown) or contralateral kidneys (Fig. 1B) . This discrepancy might be due to the difference in the sensitivity of the antibodies used or the difference of rat strain (Sprague-Dawley rats vs. Wistar rats). In contrast, the expressions of L-type Ca 2ϩ channels as well as N-type Ca 2ϩ channels were upregulated in UUO kidneys (Fig. 1B) . Quantitative analysis demonstrated that production of both L-type and N-type Ca 2ϩ channels was significantly elevated in UUO kidneys compared with that in contralateral kidneys (Fig. 1C) . We next examined the localization of L-type and N-type Ca ␣-SMA-positive vessels (Fig. 1D) . In normal and contralateral kidneys, N-type Ca 2ϩ channels were present in THP-positive tubular cells and ␣-SMA-positive vessels but not in glomeruli or other portions of the nephron segment (data not shown). In contrast, expression of N-type Ca 2ϩ channels was clearly detectable in AQP1-positive proximal tubular cells and AQP2-positive collecting ducts in UUO kidneys (Fig. 1E) . These results suggest that both L-type and N-type Ca 2ϩ channels are involved in a process of renal fibrosis.
RESULTS
Expression and localization of L-type and N-type
Effects of amlodipine and cilnidipine on histological changes in UUO kidneys. To examine the role of N-type Ca 2ϩ channels in renal fibrosis, we administered amlodipine, an L-type Ca 2ϩ channel blocker, and cilnidipine, a dual L/N-type Ca 2ϩ channel blocker, to UUO rats and examined the difference between the effects of amlodipine and cilnidipine on fibrotic changes after UUO. The weight of the obstructed kidney was significantly increased compared with contralateral kidney. The weight of cilnidipine-treated or amlodipine-treated obstructed kidney was significantly reduced compared with the untreated obstructed kidney ( Fig. 2A) . Serum creatinine level in UUO rats was significantly elevated compared with that in sham-operated rats. Both cilnidipine and amlodipine did not affect serum creatinine level. In contrast, blood urea nitrogen level in the cilnidipine-treated or amlodipine-treated UUO rats was slightly elevated compared with that in the untreated rats (Fig. 2B) . UUO did not significantly alter mean blood pressure (baseline vs. 14 days: 106.4 Ϯ 7.2 vs. 102.7 Ϯ 7.6 mmHg). At 14 days after UUO, there was no significant difference in mean blood pressure among UUO rats in the untreated, cilnidipine-treated, and amlodipine-treated groups (data not shown).
We assessed the fibrotic area in kidneys after UUO by Masson's trichrome staining. Interstitial fibrotic changes were observed in the untreated, cilnidipine-treated, and amlodipinetreated UUO kidneys (Fig. 2C) . Quantitative analysis showed that the fibrotic area was significantly lower in the cilnidipinetreated UUO kidneys as well as in the amlodipine-treated UUO kidneys when compared with the untreated UUO kidneys (Fig.  2D) . The fibrotic area in the cilnidipine-treated UUO kidneys was significantly lower than that in the amlodipine-treated UUO kidneys (Fig. 2D) .
We also examined the expressions of type I and type III collagen in UUO kidneys by immunostaining. The expression of type I collagen, which was undetectable in contralateral kidneys, was upregulated in UUO kidneys (Fig. 2E) . Quantitative analysis showed that type I collagen-positive area in the cilnidipine-treated and amlodipine-treated UUO kidneys was lower than that in the untreated UUO kidneys, but the difference was significant only between cilnidipine-treated and untreated UUO kidneys (Fig. 2F) . Type III collagen-positive area was also undetectable in contralateral kidneys but was upregulated in UUO kidneys (Fig. 2E) . Quantitatively, the expression of type III collagen in the both cilnidipine-treated and amlo- dipine-treated UUO kidneys was significantly lower than that in the untreated UUO kidneys (Fig. 2G) .
Effects of amlodipine and cilnidipine on ␣-SMA expression in UUO kidneys. During renal fibrosis, tubular cells transdifferentiate into fibroblastic cells and express ␣-SMA, a marker of myofibroblasts. We next examined the effects of amlodipine and cilnidipine on ␣-SMA expression in UUO kidneys. In normal (Fig. 3Ad) and contralateral kidneys (data not shown), ␣-SMA expression was scarcely observed. In contrast, the expression of ␣-SMA was upregulated in the interstitium of UUO kidneys (Fig. 3, Aa-Ac) . The area of ␣-SMA expression was significantly reduced in cilnidipine-treated and amlodipine-treated UUO kidneys (Fig. 3B) . Western blot analysis also confirmed a significant decrease in the expression of ␣-SMA in cilnidipine-treated as well as in amlodipine-treated UUO kidneys (Fig. 3, C and D) .
Effects of amlodipine and cilnidipine on E-cadherin expression in UUO kidneys. We also examined the effects of amlodipine and cilnidipine on the expression of E-cadherin, a key epithelial cell adhesion molecule, in UUO kidneys. There were no significant differences in the expression of E-cadherin among the untreated, cilnidipine-treated, and amlodipinetreated UUO kidneys (data not shown).
Effects of amlodipine and cilnidipine on cell proliferation in UUO kidneys. We further examined the effects of amlodipine and cilnidipine on cell proliferation in UUO kidneys by PCNA staining. In normal (data not shown), sham-operated (Fig. 4Ad) , and contralateral kidneys (Fig. 4Aa) , PCNA-positive cells were scarcely observed. In contrast, a large number of PCNA-positive cells were present in UUO kidneys (Fig. 4Ab) . Tubular and interstitial cells were positive for PCNA (Fig. 4Ac) . Neither cilnidipine nor amlodipine affected the number of tubular PCNApositive cells (Fig. 4B ), but they significantly reduced the number of interstitial PCNA-positive cells (Fig. 4C) .
Effects of amlodipine and cilnidipine on macrophage infiltration in UUO kidneys. Macrophage infiltration is often correlated with degree of renal fibrosis, and depletion of macrophages reduces fibrosis in several disease models (23) . We finally investigated CD68-positive macrophage infiltration in UUO kidneys (Fig. 5) . Macrophage infiltration was not observed in normal and contralateral kidneys but was detectable in UUO kidneys (Fig. 5A) . The number of infiltrating macrophages was significantly lower in cilnidipine-treated UUO kidneys but not in amlodipine-treated UUO kidneys (Fig. 5B) .
EMT in UUO kidneys. Using the BrdU labeling method, we previously demonstrated that LRCs act as renal progenitor-like tubular cells (20) and found that tubular LRCs migrated into the interstitium of the kidneys after UUO (32), suggesting that LRCs undergo EMT during renal fibrosis. We next examined the presence of LRCs in the kidney after UUO. BrdU was injected into normal rats for 7 days. After a 2-wk chase period, UUO was generated in these rats. BrdU-positive cells could be identified as LRCs, because rapidly proliferating cells divided many times during the chase period and incorporated BrdU was diluted out. LRCs were mainly localized in proximal tubular cells in normal (data not shown), sham-operated, and contralateral kidneys (Fig. 6A) . No LRCs was detected in the glomeruli, capillary endothelial cells, or interstitium (data not shown). At 7 days after UUO, LRCs remained localized in the tubules, but some LRCs were found to be present in the interstitium along the destroyed basement membrane (Fig. 6A) .
We also examined the localization of LRCs and laminin or type IV collagen basement membrane in the UUO kidneys (Fig. 6B) . In normal and contralateral kidneys, LRCs were localized within the basement membrane. In contrast, LRCs were present in the interstitium adjacent to the laminin-positive or type IV collagen-positive basement membrane in the UUO kidneys, thus suggesting our previous notion (32) that tubular LRCs migrate into the interstitium of the kidney after UUO.
We investigated the phenotype of LRCs in UUO kidneys. LRCs were colocalized with ␣-SMA (a marker of myofibroblasts) and vimentin (a mesenchymal marker; Fig. 6C ). LRCs were also found to express extracellular matrix such as type I collagen, type III collagen, and fibronectin (Fig. 6C) . Collectively, these findings suggest that LRCs undergo EMT during renal fibrosis.
Effects of amlodipine and cilnidipine on EMT. We finally tested the effect of amlodipine and cilnidipine on EMT in UUO rats treated with BrdU for 1 wk, followed by a 2-wk chase period. The number of interstitial LRCs in cilnidipine-treated, but not in amlodipine-treated, UUO kidneys was significantly decreased compared with the untreated UUO kidneys (Fig.  6D) , suggesting the possibility that EMT in UUO kidneys was reduced by cilnidipine. The number of tubular LRCs was reduced in both cilnidipine-treated and amlodipine-treated UUO kidneys, compared with that in the untreated UUO kidneys (Fig. 6E) .
DISCUSSION
Generally, UUO-treated rats do not show hypertensive phenotype as shown in this study, making it difficult to observe blood pressure-lowering effect of antihypertensive drugs. In the present study, UUO rats were treated with cilnidipine or amlodipine at the dose of 3 mg·kg Ϫ1 ·day Ϫ1 for 14 days. Several previous reports demonstrated that cilnidipine and amlodipine had a lowering effect of blood pressure to a similar extent at the dose used in this study (3 mg·kg Ϫ1 ·day Ϫ1 ) in hypertensive rats (12, 25, 26) . Previous pharmacological study also demonstrated that cilnidipine and amlodipine inhibited L-type Ca channel current to a similar extent using a whole cell patch-clamp technique (29) . Taken together, we speculate that both Ca 2ϩ channel blockers inhibited L-type Ca channel to a similar extent in this study, although the blood pressurelowering effects of cilnidipine as well as amlodipine could not be observed at this dose.
EMT is a process by which differentiated epithelial cells undergo a phenotypic conversion that gives rise to matrixproducing fibroblasts and myofibroblasts during renal fibrosis (16) . In the present study, consistent with previous reports (20, 32) , we demonstrated that LRCs are present in tubules of normal rat kidneys using in vivo labeling with BrdU. LRCs migrated into the interstitium through the damaged tubular basement membrane after UUO. The number of interstitial LRCs in UUO kidneys was significantly reduced by treatment with cilnidipine but not with amlodipine (Fig. 6) . In addition to L-type Ca 2ϩ channels, cilnidipine inhibits N-type Ca 2ϩ channels in various types of neuron (7, 28) . Therefore, inhibition of LRC migration by cilnidipine may be mediated by the blockade of N-type Ca 2ϩ channels. The mechanism is unclear by which cilnidipine inhibited LRC migration into the intersti- tium. The function of Ca 2ϩ channels is closely related to the actin cytoskeleton reorganization required for cell migration (24) . In UUO kidneys, N-type Ca 2ϩ channels are upregulated in proximal tubules (Fig. 1C) , where most LRCs are localized. The changes in intracellular Ca 2ϩ concentration via N-type Ca 2ϩ channels may be involved in cell migration or transdifferentiation of LRCs.
Activation of the RAS is thought to be responsible for initiating tubulointerstitial fibrosis and subsequent deterioration of renal function. Angiotensin II induces infiltration of macrophages, a critical determinant of fibrogenesis, into the injured tissues (15) . It has been reported that angiotensin II receptor blockers ameliorate renal function and decelerate progression of renal disease. In the kidney, sympathetic nerves are distributed to both afferent and efferent arterioles in the glomeruli (5) . Renal sympathetic nerve activation decreases renal blood flow and glomerular filtration rate by constricting renal vasculature and activates the RAS by stimulating renin release from juxtaglomerular granular cells. It has been reported that cilnidipine suppresses RAS hyperactivity through its sympatholytic action (12) . When compared with amlodipine, cilnidipine leads to weaker activation of the RAS in human patients (14) , and the renotropic action of cilnidipine has been implicated in the reduction of RAS activity (13) , suggesting that reduction of renal fibrosis, EMT, and macrophage infiltration by cilnidipine is via suppression of RAS activity in UUO kidneys. However, this is unlikely, as we could not find significant differences in expression levels of angiotensinconverting enzyme, angiotensinogen, and renin among the untreated, cilnidipine-treated, and amlodipine-treated UUO kidneys (unpublished observation). The dose of cilnidipine used in this study did not significantly alter blood pressure; thus the antifibrotic effects of cilnidipine are probably mediated by direct action on N-type Ca 2ϩ channel-expressing tubular cells, rather than via its hemodynamic action or modulation of RAS activity through its sympatholytic action.
Contribution of N-type Ca 2ϩ channels to tissue injury has been demonstrated in several organs. After ischemic injury, expression of N-type Ca 2ϩ channels was elevated in brain regions susceptible to ischemia (3), and a selective N-type Ca 2ϩ channel antagonist was found to protect against ischemic brain injury (2, 30). In DOCA-salt hypertensive rats, myocardial fibrosis was significantly improved by cilnidipine, thus suggesting the protective effects of cilnidipine on cardiovascular remodeling (11) . Several reports have also demonstrated that N-type Ca 2ϩ channels play a role in renal injury. Immunoreactivity for N-type Ca 2ϩ channels was observed in glomerular podocytes in spontaneously hypertensive rats, and cilnidipine suppressed the development of proteinuria by inhibiting podocyte injury (6). Cilnidipine was more effective than amlodipine at preventing the progression of proteinuria in hypertensive patients when coupled with a RAS inhibitor (27) , probably because cilnidipine inhibited renal sympathetic nerve activity (13) , resulting in the vasodilation of efferent arterioles and the attenuation of glomerular hypertension (34) . Cilnidipine was reported to improve renal function and arterial stiffness in patients with essential hypertension (22) . Consistent with these data, we found the beneficial effect of cilnidipine on renal fibrosis in the present study. We demonstrated the upregulated expressions of L-type and N-type Ca 2ϩ channels in UUO kidneys (Fig. 1) . Cilnidipine (a dual L/N-type Ca 2ϩ channel blocker) has antifibrotic action, which was more potent than that of amlodipine (an L-type Ca 2ϩ channel blocker) (Fig. 2) , suggesting the possible contribution of N-type Ca 2ϩ channels to renal fibrosis. Both amlodipine and cilnidipine significantly reduced the type III collagen deposition, ␣-SMA expression, and interstitial cell proliferation in UUO kidneys (Figs. 2-4) . Cilnidipine provided additional antifibrotic effects, including reductions in the deposition of type I collagen (Fig. 2) and macrophage infiltration (Fig. 5) and decreases in the number of interstitial LRCs (Fig. 6) in UUO kidneys. These findings suggest that N-type Ca 2ϩ channels play a role in multiple steps of renal fibrosis. Its blockade may be a useful therapeutic approach for the prevention of renal fibrosis. This study did not clarify the detailed mechanism by which cilnidipine inhibited renal fibrosis. To this end, the role of N-type Ca 2ϩ channels in inflammation, EMT, and extracellular matrix production during renal fibrosis should be analyzed independently. Mutant mice lacking N-type Ca 2ϩ channels will also be useful. Further study will be needed to address this issue.
